# US 2010/0143311 A1 · Anticancer therapy by transplanting vascular endothelial progenitor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143311 A1
- Document ID: US20100143311A1
- Status: Published application
- Kind: A1
- Application number: 12/600,530
- Filed: 2008-05-19
- Published: 2010-06-10
- Earliest claimed: 2007-05-18
- Assignees: National University Corporation Asahikawa Medical
- Inventors: Yusuke Mizukami; Yutaka Kohgo; Kazumasa Nakamura
- Web page: https://patentgrep.com/patent/US20100143311A1

## CPC

- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

It is intended to provide anticancer therapy using autologous cells or the like, which induces the regression of cancer or has favorable drug delivery effects and brings about reduction or withdrawal of a hypoxic region(s) in tumor. Transplantation of endothelial progenitor cells, via intravenously or other methods leads to tumor growth inhibition, an increase of the vascular density with an enlargement of the vascular diameter, and reduction of a hypoxic region(s) in the tumor. Allogeneic transplantation of endothelial progenitor cells may be achieved to secure the cells for the therapy, however, autologous transplantation of endothelial progenitor cells from cancer patients would be desirable in order to evade rejection. When the autologous cells are used, mononuclear cells are separated from the peripheral blood or bone marrow of the patient and cultured using an endothelial differentiation medium containing cytokines such as VEGF to obtain adherent cells, which can then be collected and advantageously used as endothelial progenitor cells.

## Claims

### Claim 1

A method for preventing or treating tumor, comprising administering endothelial progenitor cells to a mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein administered endothelial progenitor cells inhibit tumor growth.

### Claim 3 (depends on 1)

The method of claim 1, wherein administered endothelial progenitor cells reduce a hypoxic region(s) in tumor.

### Claim 4 (depends on 1)

The method of claim 1, wherein administered endothelial progenitor cells induce remodeling of tumor vessels.

### Claim 5

A method for enhancing activity of an anticancer agent(s) comprising administering endothelial progenitor cells to a mammal.

### Claim 6

A method for enhancing effect of radiotherapy, comprising administering endothelial progenitor cells to a mammal.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the endothelial progenitor cells are administered transvenously.

### Claim 10 (depends on 1)

The method of claim 1, wherein the tumor is selected from the group consisting of pancreatic cancer, esophagus cancer, gastric cancer, lung cancer, kidney cancer, thyroid cancer, parotid cancer, head and neck cancer, bone and soft tissue sarcoma, ureter cancer, bladder cancer, uterine cancer, liver cancer, breast cancer, ovarian cancer, and uterine tube cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the tumor is pancreatic cancer.

### Claim 12 (depends on 1)

The method of claim 1 further comprising administering an anticancer agent(s) to the mammal, wherein activity of said anticancer agent(s) is enhanced by the administered endothelial progenitor cells.

### Claim 13 (depends on 1)

The method of claim 1 which is combined with radiotherapy, wherein effect of said radiotherapy is enhanced by the administered endothelial progenitor cells.

### Claim 14 (depends on 5)

The method of claim 5 wherein the endothelial progenitor cells are administered transvenously.

### Claim 15 (depends on 5)

The method of claim 5, wherein the tumor is selected from the group consisting of pancreatic cancer, esophagus cancer, gastric cancer, lung cancer, kidney cancer, thyroid cancer, parotid cancer, head and neck cancer, bone and soft tissue sarcoma, ureter cancer, bladder cancer, uterine cancer, liver cancer, breast cancer, ovarian cancer, and uterine tube cancer.

### Claim 16 (depends on 5)

The method of claim 5, wherein the tumor is pancreatic cancer.

### Claim 17 (depends on 6)

The method of claim 6 wherein the endothelial progenitor cells are administered transvenously.

### Claim 18 (depends on 6)

The method of claim 6, wherein the tumor is selected from the group consisting of pancreatic cancer, esophagus cancer, gastric cancer, lung cancer, kidney cancer, thyroid cancer, parotid cancer, head and neck cancer, bone and soft tissue sarcoma, ureter cancer, bladder cancer, uterine cancer, liver cancer, breast cancer, ovarian cancer, and uterine tube cancer.

### Claim 19 (depends on 6)

The method of claim 6, wherein the tumor is pancreatic cancer.
